Genfit set to raise $100m in Nasdaq IPOFrench Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US. more ➔
Targeting NFkappaB protects tendons from i...Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation. more ➔
Anaveon bags CHF35m series A financingUniversity Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist. more ➔
AMR network CARB-X expands reachThe global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR). more ➔
Roche swallows Spark Therapeutics in $4.3b...Swiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn. more ➔
How salt triggers allergySodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells. more ➔
Calypso Biotech cash in €20M Series A fi...Dutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation … more ➔
Evotec and HZI join forces in antibiotics...Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs. more ➔
First immunotolerant allogenic cell transp...Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants. more ➔
Arvelle Therapeutics raises $180m in Serie...Swiss newco Arvelle Therapeutics has baged a $180m (€159.1m) series A financing led by LSP. The company licenced the anti-epileptic candidate cenobamate (YKP3089) for $100m (€88.4m) upfront … more ➔
